Perspectives  ||| S:0 E:13 ||| NNP
of  ||| S:13 E:16 ||| IN
1H-NMR-based  ||| S:16 E:29 ||| FW
urinary  ||| S:29 E:37 ||| FW
metabonomics  ||| S:37 E:50 ||| FW
in  ||| S:50 E:53 ||| FW
Fabry  ||| S:53 E:59 ||| FW
disease  ||| S:59 E:67 ||| FW
High  ||| S:67 E:72 ||| FW
resolution  ||| S:72 E:83 ||| FW
proton  ||| S:83 E:90 ||| FW
magnetic  ||| S:90 E:99 ||| FW
resonance  ||| S:99 E:109 ||| FW
spectroscopy  ||| S:109 E:122 ||| FW
( ||| S:122 E:123 ||| -LRB-
1H-NMR ||| S:123 E:129 ||| NNP
)  ||| S:129 E:131 ||| -RRB-
of  ||| S:131 E:134 ||| IN
body  ||| S:134 E:139 ||| NN
fluids  ||| S:139 E:146 ||| VBZ
coupled  ||| S:146 E:154 ||| VBN
with  ||| S:154 E:159 ||| IN
multivariate  ||| S:159 E:172 ||| JJ
data  ||| S:172 E:177 ||| NN
analysis  ||| S:177 E:186 ||| NN
has  ||| S:186 E:190 ||| VBZ
led  ||| S:190 E:194 ||| VBN
to  ||| S:194 E:197 ||| TO
a  ||| S:197 E:199 ||| DT
new  ||| S:199 E:203 ||| JJ
science  ||| S:203 E:211 ||| NN
known  ||| S:211 E:217 ||| VBN
as  ||| S:217 E:220 ||| IN
metabonomics ||| S:220 E:232 ||| NN
.  ||| S:232 E:234 ||| .
Metabonomics  ||| S:234 E:247 ||| NNP
is  ||| S:247 E:250 ||| VBZ
a  ||| S:250 E:252 ||| DT
powerful  ||| S:252 E:261 ||| JJ
tool  ||| S:261 E:266 ||| NN
for  ||| S:266 E:270 ||| IN
investigating  ||| S:270 E:284 ||| VBG
any  ||| S:284 E:288 ||| DT
disturbance  ||| S:288 E:300 ||| NN
in  ||| S:300 E:303 ||| IN
the  ||| S:303 E:307 ||| DT
normal  ||| S:307 E:314 ||| JJ
homeostasis  ||| S:314 E:326 ||| NN
of  ||| S:326 E:329 ||| IN
biochemical  ||| S:329 E:341 ||| JJ
processes ||| S:341 E:350 ||| NNS
.  ||| S:350 E:352 ||| .
In  ||| S:352 E:355 ||| IN
particular ||| S:355 E:365 ||| JJ
,  ||| S:365 E:367 ||| ,
urine  ||| S:367 E:373 ||| JJ
metabonomics  ||| S:373 E:386 ||| NN
provides  ||| S:386 E:395 ||| VBZ
information  ||| S:395 E:407 ||| NN
on  ||| S:407 E:410 ||| IN
the  ||| S:410 E:414 ||| DT
metabolite  ||| S:414 E:425 ||| JJ
phenotype  ||| S:425 E:435 ||| NN
of  ||| S:435 E:438 ||| IN
the  ||| S:438 E:442 ||| DT
human  ||| S:442 E:448 ||| JJ
being  ||| S:448 E:454 ||| NN
and  ||| S:454 E:458 ||| CC
is  ||| S:458 E:461 ||| VBZ
therefore  ||| S:461 E:471 ||| RB
appropriate  ||| S:471 E:483 ||| JJ
to  ||| S:483 E:486 ||| TO
study  ||| S:486 E:492 ||| VB
the  ||| S:492 E:496 ||| DT
status  ||| S:496 E:503 ||| NN
of  ||| S:503 E:506 ||| IN
the  ||| S:506 E:510 ||| DT
global  ||| S:510 E:517 ||| JJ
system ||| S:517 E:523 ||| NN
.  ||| S:523 E:525 ||| .
Here  ||| S:525 E:530 ||| RB
we  ||| S:530 E:533 ||| PRP
applied  ||| S:533 E:541 ||| VBD
1H-NMR-based  ||| S:541 E:554 ||| CD
urinary  ||| S:554 E:562 ||| JJ
metabonomics  ||| S:562 E:575 ||| NN
in  ||| S:575 E:578 ||| IN
a  ||| S:578 E:580 ||| DT
perspective  ||| S:580 E:592 ||| NN
study  ||| S:592 E:598 ||| NN
of  ||| S:598 E:601 ||| IN
the  ||| S:601 E:605 ||| DT
inherited  ||| S:605 E:615 ||| JJ
lysosomal  ||| S:615 E:625 ||| JJ
storage  ||| S:625 E:633 ||| NN
disorder  ||| S:633 E:642 ||| NN
known  ||| S:642 E:648 ||| VBN
as  ||| S:648 E:651 ||| IN
Fabry  ||| S:651 E:657 ||| NNP
disease ||| S:657 E:664 ||| NN
,  ||| S:664 E:666 ||| ,
starting  ||| S:666 E:675 ||| VBG
from  ||| S:675 E:680 ||| IN
the  ||| S:680 E:684 ||| DT
metabolite  ||| S:684 E:695 ||| JJ
profiling  ||| S:695 E:705 ||| NN
of  ||| S:705 E:708 ||| IN
urine  ||| S:708 E:714 ||| JJ
samples  ||| S:714 E:722 ||| NNS
of  ||| S:722 E:725 ||| IN
male  ||| S:725 E:730 ||| JJ
and  ||| S:730 E:734 ||| CC
female  ||| S:734 E:741 ||| JJ
na√Øve  ||| S:741 E:747 ||| JJ
Fabry  ||| S:747 E:753 ||| JJ
subjects ||| S:753 E:761 ||| NNS
.  ||| S:761 E:763 ||| .
Here  ||| S:763 E:768 ||| RB
we  ||| S:768 E:771 ||| PRP
show  ||| S:771 E:776 ||| VBP
that  ||| S:776 E:781 ||| IN
the  ||| S:781 E:785 ||| DT
2  ||| S:785 E:787 ||| CD
groups  ||| S:787 E:794 ||| NNS
of  ||| S:794 E:797 ||| IN
patients  ||| S:797 E:806 ||| NNS
can  ||| S:806 E:810 ||| MD
be  ||| S:810 E:813 ||| VB
fairly  ||| S:813 E:820 ||| RB
clearly  ||| S:820 E:828 ||| RB
separated  ||| S:828 E:838 ||| VBN
into  ||| S:838 E:843 ||| IN
2  ||| S:843 E:845 ||| CD
classes  ||| S:845 E:853 ||| NNS
due  ||| S:853 E:857 ||| JJ
to  ||| S:857 E:860 ||| TO
statistically  ||| S:860 E:874 ||| VB
significant  ||| S:874 E:886 ||| JJ
differences  ||| S:886 E:898 ||| NNS
in  ||| S:898 E:901 ||| IN
the  ||| S:901 E:905 ||| DT
urinary  ||| S:905 E:913 ||| JJ
level  ||| S:913 E:919 ||| NN
of  ||| S:919 E:922 ||| IN
some  ||| S:922 E:927 ||| DT
metabolites ||| S:927 E:938 ||| NN
.  ||| S:938 E:940 ||| .
This  ||| S:940 E:945 ||| DT
preliminary  ||| S:945 E:957 ||| JJ
study  ||| S:957 E:963 ||| NN
shows  ||| S:963 E:969 ||| VBZ
that  ||| S:969 E:974 ||| DT
metabonomics  ||| S:974 E:987 ||| NN
can  ||| S:987 E:991 ||| MD
potentially  ||| S:991 E:1003 ||| RB
be  ||| S:1003 E:1006 ||| VB
used  ||| S:1006 E:1011 ||| VBN
for  ||| S:1011 E:1015 ||| IN
characterizing  ||| S:1015 E:1030 ||| VBG
the  ||| S:1030 E:1034 ||| DT
biochemical  ||| S:1034 E:1046 ||| JJ
mechanisms  ||| S:1046 E:1057 ||| NNS
underlying  ||| S:1057 E:1068 ||| VBG
the  ||| S:1068 E:1072 ||| DT
disease  ||| S:1072 E:1080 ||| NN
and ||| S:1080 E:1083 ||| CC
,  ||| S:1083 E:1085 ||| ,
hopefully ||| S:1085 E:1094 ||| RB
,  ||| S:1094 E:1096 ||| ,
for  ||| S:1096 E:1100 ||| IN
early  ||| S:1100 E:1106 ||| JJ
diagnosis  ||| S:1106 E:1116 ||| NN
of  ||| S:1116 E:1119 ||| IN
Fabry  ||| S:1119 E:1125 ||| NNP
disease ||| S:1125 E:1132 ||| NN
.  ||| S:1132 E:1134 ||| .
